drugset
Drugs / HSG4112
last change Apr 2023 re-read 3 minutes ago

HSG4112

Developed for
obesity disorder
Investigated by
Glaceum · Seoul National University Hospital · Kyungpook National University Hospital · Gangnam Severance Hospital · Korea University Anam Hospital · SMG-SNU Boramae Medical Center
+1 more · Seoul National University Bundang Hospital

Trials 5

today NCT05310032 · Ph 1 NCT05197556 · Ph 2 NCT04703764 · Ph 1 NCT04733001 · Ph 1 NCT04732988 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT05310032 Apr → Dec 2022 obesity disorder Glaceum Completed No outcome recorded
Phase 1 NCT04703764 Feb 2021 → Jan 2022 obesity disorder Glaceum Completed No outcome recorded
Phase 1 NCT04733001 Jul 2020 → Feb 2021 obesity disorder Glaceum Completed No outcome recorded
Phase 1 NCT04732988 Aug 2018 → May 2021 obesity disorder Glaceum Completed No outcome recorded
Phase 21 trial
Phase 2 NCT05197556 Feb → Dec 2022 obesity disorder Glaceum Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as HSG4112 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04733001 ↗
4

NCT04732988 ↗

NCT05197556 ↗

NCT05310032 ↗

NCT04703764 ↗
Route Oral “via once-daily oral administration” NCT04703764 ↗